Answering the narrow version, because the broad one does not have a single answer. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.
I have used three payment routes and the only thing that changed with each was how much leverage I had when something went wrong.
So the question, as narrowly as I can put it: how people are thinking about the trade-off between reversibility and privacy, because you cannot have both.
Numbers rather than impressions, if you have them.
Dr.ObesityLA said:Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third…
Correct as far as it goes. The part it does not cover is what to do when the honest answer is "not enough data", which is more often than anyone likes.
PeptideMeter — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsDr.EndoEP said:I have used three payment routes and the only thing that changed with each was how much leverage I had when something went wrong.
Second this.
Adding the clinical framing, because it changes how the question reads. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.